These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
12. Multiple mutations in katG and inhA identified in Thai isoniazid-resistant Mycobacterium tuberculosis isolates. Khadka DK; Eampokalap B; Panitchakorn J; Ramasoota P; Khusmith S Southeast Asian J Trop Med Public Health; 2007 Mar; 38(2):376-82. PubMed ID: 17539290 [TBL] [Abstract][Full Text] [Related]
13. Detection of multidrug resistance in Mycobacterium tuberculosis. Sekiguchi J; Miyoshi-Akiyama T; Augustynowicz-Kopeć E; Zwolska Z; Kirikae F; Toyota E; Kobayashi I; Morita K; Kudo K; Kato S; Kuratsuji T; Mori T; Kirikae T J Clin Microbiol; 2007 Jan; 45(1):179-92. PubMed ID: 17108078 [TBL] [Abstract][Full Text] [Related]
14. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant. Zhao X; Yu H; Yu S; Wang F; Sacchettini JC; Magliozzo RS Biochemistry; 2006 Apr; 45(13):4131-40. PubMed ID: 16566587 [TBL] [Abstract][Full Text] [Related]
15. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains]. Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015 [TBL] [Abstract][Full Text] [Related]
16. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands. van Doorn HR; de Haas PE; Kremer K; Vandenbroucke-Grauls CM; Borgdorff MW; van Soolingen D Clin Microbiol Infect; 2006 Aug; 12(8):769-75. PubMed ID: 16842572 [TBL] [Abstract][Full Text] [Related]
17. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study]. Yoshiyama T; Ogata H; Ito K; Aono A; Wada M Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318 [TBL] [Abstract][Full Text] [Related]
18. Study of resistance to anti-tuberculosis drugs in five districts of Equatorial Guinea: rates, risk factors, genotyping of gene mutations and molecular epidemiology. Tudó G; González J; Obama R; Rodríguez JM; Franco JR; Espasa M; Simarro PR; Escaramís G; Ascaso C; García A; Jiménez de Anta MT Int J Tuberc Lung Dis; 2004 Jan; 8(1):15-22. PubMed ID: 14974741 [TBL] [Abstract][Full Text] [Related]
19. Mutations responsible for Mycobacterium tuberculosis isoniazid resistance in Italy. Rindi L; Bianchi L; Tortoli E; Lari N; Bonanni D; Garzelli C Int J Tuberc Lung Dis; 2005 Jan; 9(1):94-7. PubMed ID: 15675557 [TBL] [Abstract][Full Text] [Related]
20. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]